AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02630225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~1. All necessary medical care and scheduled follow-ups with subspecialty services~2. Evaluation by social work with referral to appropriate community services~3. Screening for alcohol use~4. Discharge planning services~5. Financial counseling
Study NCT02630225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~1. All necessary medical care and scheduled follow-ups with subspecialty services~2. Evaluation by social work with referral to appropriate community services~3. Screening for alcohol use~4. Discharge planning services~5. Financial counseling
Study NCT02630225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
Study NCT02630225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Agency Attention
Description: Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
Study NCT00288067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given PO
Study NCT00288067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01433445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given 3 times a week, every other week in 28-day cycles.
Study NCT01433445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Given twice daily in 28-day cycles.
Study NCT03587883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols I
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
Study NCT03587883 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control I
Description: Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
Study NCT03587883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols II
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
Study NCT03587883 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control II
Description: Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
Study NCT01943968 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Study NCT01607060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulone
Description: Patients will receive lactulone to daily laxation
Study NCT01607060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulone
Description: Patients will receive lactulone to daily laxation
Study NCT03804996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1801
Description: Intravenous infusion over 1 hour every 4 weeks
Study NCT03804996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
Study NCT03298620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Study NCT03298620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Manual toothbrush
Study NCT02471885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning
Description: each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10\^9/L; skip RIC if platelets \< 50 x 10\^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
Study NCT02471885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
Study NCT01596283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard fluid management
Description: The patient will receive standard fluid management
Study NCT01596283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goal directed fluid therapy with the Edwards EV1000 system
Description: This arm will have fluid therapy guided by the Edwards EV1000 system.
Study NCT01614977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisoline
Description: Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
Study NCT02682212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Description: Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
Study NCT00857805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
Study NCT00857805 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiotherapy
Description: Fifteen consecutive sessions
Study NCT03855163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspection visits
Description: Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
Study NCT03855163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance workshops
Description: Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
Study NCT03855163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online risk assessment tool
Description: Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
Study NCT05764226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35(L20200708MP07707, Ministry of Health, Mongolia)was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
Description: One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.
Study NCT01486758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
Study NCT01486758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01743300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
Study NCT01743300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
Study NCT01743300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
Study NCT01743300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit juice
Description: The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
Study NCT03240536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choosing Wisely form
Description: The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~1. Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~2. Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~3. Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management.
Study NCT03020329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily.
Study NCT03020329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
Study NCT03020329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fu
Description: Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
Study NCT03020329 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Description: Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
Study NCT02813967 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 54 Gy
Description: Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
Study NCT02813967 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 60 Gy
Description: Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
Study NCT02813967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 70mg/m2 was administered on days 1-14 and 29-42.
Study NCT03605160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional polish
Description: After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
Study NCT03605160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid-jet
Description: After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
Study NCT00749216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Study NCT01686165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study NCT01686165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01686165 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT05081505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural exercise course
Description: 12-week structured exercise class, team competition, social support, and incentive strategy
Study NCT05081505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomous group class
Description: 12-week autonomous group class, team competition, social support, and incentive strategy
Study NCT01110083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1204831
Description: Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
Study NCT04316728 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VivaDiag™ COVID-19 lgM/IgG Rapid Test
Description: VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
Study NCT02494921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Given IV
Study NCT02494921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given Orally
Study NCT02494921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given Orally
Study NCT02494921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV
Study NCT02859467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping and Inhibitory Treatment Techniques
Description: Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~* Release Technique of the trapezius muscle.~* Release Technique for scalene muscles.~* Technique suboccipital inhibition.~* Technique hands crossed for induction dorsal superficial fascia.
Study NCT02859467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Electrical Stimulation Therapy
Description: Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
Study NCT03729921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric variceal ligation
Description: The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.
Study NCT03729921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric variceal obturation
Description: Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
Study NCT01551316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221
Description: This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
Study NCT01551316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
Study NCT04130334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
Description: After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
Study NCT04130334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: : After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
Description: : After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
Study NCT01676532 — intervention group
Intervention type: OTHER
Intervention: Students attending SBHC
Description: School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
Study NCT05516368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
Study NCT01732146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin Beta
Description: erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
Study NCT01732146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02643719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
Study NCT02643719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)
Study NCT02643719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
Study NCT02643719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abortive Medication (Naproxen and Sumatriptan)
Description: All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
Study NCT02416882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercise
Description: Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
Study NCT02416882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Exercise
Description: Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
Study NCT02416882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary Option
Description: Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
Study NCT03886519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BRAP (Bevel/rotate/advance procedure)
Description: Trichiasis surgery using the BRAP procedure
Study NCT03886519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabut
Description: Trichiasis surgery using the Trabut procedure
Study NCT02339324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and high dose interferon alfa-2b (HDI)
Description: Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
Study NCT02377479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Taken for controlled ovarian hyperstimulation.
Study NCT02377479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Taken for controlled ovarian hyperstimulation.
Study NCT02377479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Taken for controlled ovarian hyperstimulation
Study NCT02377479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Taken for controlled ovarian hyperstimulation